$Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine$

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine

Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug...

Full description

Saved in:

Bibliographic Details
Main Authors:	Saif Khan, Suresh Babu Jandrajupalli, Nashwa Zaki Ali Bushara, Rama Devi Patel Raja, Shadab Mirza, Kuldeep Sharma, Rajan Verma, Ashish Kumar, Mohtashim Lohani
Format:	Article
Language:	English
Published:	MDPI AG 2024-12-01
Series:	Cells
Subjects:	triple-negative breast cancer (TNBC) antibody–drug conjugates sacituzumab govitecan neutropenia ADC sequencing resistance
Online Access:	https://www.mdpi.com/2073-4409/13/24/2126
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis
by: Maria Inez Dacoregio, et al.
Published: (2025-02-01)

Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis
by: Yaping Zhang, et al.
Published: (2025-06-01)

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
by: George W. Jr. Sledge, et al.
Published: (2025-08-01)

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer
by: Hope S. Rugo, et al.
Published: (2025-03-01)

Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization
by: Henrike Barbara Zech, et al.
Published: (2025-05-01)

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
by: Megan H. Wong, et al.
Published: (2024-08-01)

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study
by: E. Fountzilas, et al.
Published: (2025-03-01)

Progress of antibody–drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges
by: Fanhao Zeng, et al.
Published: (2025-05-01)

A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan
by: Takamichi Ito, et al.
Published: (2025-01-01)

Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids
by: Wu Ying, et al.
Published: (2025-07-01)

Partial Response Achieved in a Case of Metastatic Triple-Negative Breast Cancer Based on the Patient-Derived Tumor Organoids
by: Liu Y, et al.
Published: (2025-07-01)

Multimodal evaluation of cerebrospinal fluid from breast cancer leptomeningeal metastases using circulating tumor cell detection, single-cell sequencing, and proteomics
by: Elnaz Rahbarlayegh, et al.
Published: (2025-07-01)

Antibody-drug conjugates in cancer therapy: applications and future advances
by: Rou Long, et al.
Published: (2025-05-01)

Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer
by: Jayakumar R. Nair, et al.
Published: (2024-12-01)

Clinical advances in antibody-drug conjugates for hematological malignancies
by: TANG Sijie, et al.
Published: (2024-12-01)

Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01)

Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024-11-01)

Development of Multifunctional Targeted Dual-Loaded Polymeric Nanoparticles for Triple-Negative Breast Cancer Treatment
by: Gantumur Battogtokh, et al.
Published: (2025-03-01)

Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report
by: Kasey C. Fitzsimmons, et al.
Published: (2025-02-01)

Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling
by: Sho Sato, et al.
Published: (2025-06-01)

Diverse Roles of Antibodies in Antibody–Drug Conjugates
by: Aiko Yamaguchi, et al.
Published: (2025-01-01)

Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses
by: Hua Wei, et al.
Published: (2025-02-01)

Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis
by: Qi Xu, et al.
Published: (2024-10-01)

Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC
by: Rodryg Ramlau, et al.
Published: (2025-08-01)

Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
by: Trudy J. Philips, et al.
Published: (2025-01-01)

First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure
by: Bożena Sikora-Kupis, et al.
Published: (2024-01-01)

Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies
by: Yuying Jiang, et al.
Published: (2025-02-01)

Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
by: Xianglong Shi, et al.
Published: (2025-02-01)

Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis
by: Wenjun Fang, et al.
Published: (2025-12-01)

MMP1-induced NF-κB activation promotes epithelial–mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer
by: Letian Chen, et al.
Published: (2025-04-01)

Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case Report
by: Daniel A. Fox, et al.
Published: (2025-02-01)

Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions
by: Fei Zhang, et al.
Published: (2025-05-01)

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects
by: Yufei Wang, et al.
Published: (2025-02-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
by: Melissa L. Johnson, et al.
Published: (2024-12-01)

Editorial: Antibody-drug conjugates in solid and hematologic malignancies
by: Khalil Saleh, et al.
Published: (2025-08-01)

Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis
by: Ali Hussain, et al.
Published: (2025-04-01)

Understanding clozapine-related blood dyscrasias. Developments, genetics, ethnicity and disparity: it's a CIN
by: Edward Silva, et al.
Published: (2025-06-01)

Transcription Factor Inhibition as a Potential Additional Mechanism of Action of Pyrrolobenzodiazepine (PBD) Dimers
by: Julia Mantaj, et al.
Published: (2025-02-01)

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
by: Quchang Ouyang, et al.
Published: (2025-06-01)